Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio Files for Hong Kong IPO; May Raise up to $500 Million

publication date: Feb 20, 2015
After two years as a private company, 3SBio, a mainland China biotech, has filed to IPO on the Hong Kong Stock Exchange. According to media reports, the company will complete a $400-$500 million initial offering in Q2. 3SBio was taken private in 2013 by its CEO, Lou Jing, and CITIC Private Equity for $370 million. Although the company remains dependent upon revenues from its two mainstay products, EPIAO and TPIAO, 3SBio has been an active dealmaker, and it now has a pipeline of 20 products in development, of which 14 are being developed as China Class I New Drugs. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital